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Abstract
The objective of this study is to examine the proportion of the total treatment effect that is attributable to contextual effects in
randomised controlled trials (RCTs) of treatments for fibromyalgia. A systematic literature search was undertaken in Medline,
Web of Science, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Allied and
Complementary Medicine in September 2015. The proportion of contextual effect (PCE) was calculated by dividing the im-
provement in the placebo arm by the improvement in the treatment arm. The measure was log-transformed for each trial and the
random effects model was used to pool data. The primary outcome was pain. Secondary outcomes were fibromyalgia impact
questionnaire (FIQ) total and fatigue. Heterogeneity was quantified using I2. Publication bias was assessed using a funnel plot and
Egger’s test. Subgroup analysis was undertaken to explore heterogeneity and potential determinants of the PCE. Fifty-one
eligible trials (9599 participants) were identified. The PCE was 0.60 (95% CI 0·56 to 0·64) for pain, 0·57 (95% CI 0·53 to 0·
61) for FIQ total, and 0·63 (95% CI 0·59 to 0·68) for fatigue. The I2 was 99.4% for pain, 99.2% for FIQ total, and 97.6% for
fatigue. More than half of the treatment effect in fibromyalgia RCTs results from non-specific contextual factors. This suggests
that optimising contextual care may enhance treatment effects and improve outcomes. Reporting the total treatment effect and the
proportion of contextual effect in trials may help to better translate research evidence into practice.
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Introduction
Fibromyalgia is a chronic painful and distressing condition
with an estimated worldwide prevalence of 2.7% [1].
Recognised risk factors include female sex, increasing age,
poor socioeconomic status, low education, and residence in
rural areas [1]. The main symptoms are multiple regional mus-
culoskeletal pain, stiffness, non-restorative sleep, fatigue, dis-
tress, and cognitive difficulties. Demonstrable abnormalities
include widespread hyperalgesia (reduced pain threshold),
allodynia, and reduced delta sleep [2]. Currently, there is no
cure and the aim of treatment is to relieve symptoms and
improve quality of life. An individualised multidisciplinary
approach combining patient education, non-pharmacological
and pharmacological treatments is recommended [3, 4].
Fibromyalgia treatments have been extensively evaluated
in randomised controlled trials (RCTs). A meta-analysis of
eight interventions (including tricyclic antidepressants, selec-
tive serotonin reuptake inhibitors, serotonin noradrenaline re-
uptake inhibitors (SNRIs), the gamma-amino butyric acid an-
alogue pregabalin, aerobic exercise, balneotherapy, cognitive
behavioural therapy (CBT), and multicomponent therapy)
found that when lower quality studies are excluded the effect
for pharmacological treatment becomes small and there is lit-
tle evidence for effect from non-pharmacological treatments
[5]. When studies with less than 100 participants in each arm
were excluded the difference between treatments and placebo
was judged to be too small to be clinically relevant.
The main focus in current reporting of RCTs is on the
separation of the treatment group from the placebo and a
treatment is deemed effective only if it is significantly better
than placebo. That is, the judgement for treatment efficacy is
based solely on the specific treatment effect. However, the
benefit that a patient experiences derives not only from the
specific effects of the treatment but also from the non-
specific effects of the context in which the treatment is de-
livered [6]. This creates an ‘efficacy paradox’ when a patient
in a clinical setting experiences significant benefit from a
treatment that has been deemed ineffective in an RCT be-
cause it did not separate sufficiently from placebo [6]. This
paradox is common with fibromyalgia, a condition that as-
sociates with a significant placebo effect in RCTs [7].
Therefore, to better reflect patient-centred experience, in-
stead of evaluating a treatment solely on the difference be-
tween treatment and placebo (specific effect), we propose to
additionally present the total treatment effect and the propor-
tion attributed to contextual effects (PCE). The concept of
PCE has been previously evaluated for the treatment of os-
teoarthritis and depression [6, 8]. Both studies revealed that
the majority of the total treatment effects were contextual
(exhibited in the placebo arm). The aim of this study was
to examine the PCE in the context of the total treatment
effect using the RCT data in fibromyalgia.
Methods
A systematic review and meta-analysis was carried out ac-
cording to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [9].
Data sources and searches
Electronic databases were used for the literature search, spe-
cifically Medline (1950–), Web of Science (1960–),
EMBASE (1980–), Cumulative Index to Nursing and Allied
Health Literature (CINAHL) (1982–), and Allied and
Complementary Medicine (1985–). For Medline, both
PubMed and OVID databases were searched. The search
was undertaken initially in December 2014 and updated in
September 2015 to identify new studies. There were no lan-
guage restrictions. All results from the database search were
exported into EndNote and duplicates were removed. Initially,
those with clearly irrelevant titles or abstracts were excluded.
If papers could not be excluded via their abstract, full-text
copies were obtained and evaluated.
Study selection
There were no age, gender, or ethnicity restrictions. There
were also no restrictions on dosage, frequency of delivery,
duration of delivery, mode of delivery, or timing of delivery.
Studies with relevant clinical outcomes were included, specif-
ically those reporting the Beck Depression Inventory, fatigue
score, Fibromyalgia Impact Questionnaire (FIQ) total, visual
analogue scale (VAS) pain scale, number of tender points,
physical function, and sleep quality. Studies with non-
clinical outcomes were not included (Fig. 1).
Only placebo-controlled trials were included to calculate
PCE in our main analysis. Any trial in which the treatment
or placebo group outcomes worsened or did not change were
discarded when calculating the PCE as the negative or zero
PCE would not permit log transformation for the meta-
analysis [10].
Treatment categoriesAll medications were categorised accord-
ing to the British National Formulary (https://www.bnf.org/).
These included antidepressants (e.g. duloxetine, amitriptyline,
fluoxetine, esreboxetine, citalopram), fibromyalgia agents (e.g.
milnacipran), anticonvulsants (e.g. gabapentin and pregabalin)
and analgesics (e.g. tramadol, acetaminophen/paracetamol,
carisoprodol, and caffeine). All remaining medications were
merged into one category as ‘others’ (dolasetron, tropisetron,
Nutropin, dehydroepiandrosterone, terguride, pyridostigmine,
cyclobenzaprine, interferon alpha). Non-pharmacological treat-
ments included acupuncture, electromagnetic therapy, and other
treatment modalities.
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Data extraction
Data were extracted by the first reviewer (NW) and validated
independently by a second reviewer (AS). Discrepancies were
discussed between the two reviewers and any disagreement
was discussed with a third reviewer (WZ). The following data
were extracted: country in which trial was performed, setting
(e.g. community or hospital), number of arms, trial design,
presence of industry funding, treatment, type of blinding,
presence of allocation concealment, use of intention to treat
analysis, duration of treatment, frequency/dose of treatment,
diagnosis method, continuation of existing therapy, age, pro-
portion of female participants, duration of fibromyalgia, num-
ber of participants, dropout rate, outcome measure descrip-
tion, and results with their standard deviations.
Quality assessment
The RCTs were assessed using the adapted Jadad scale [11].
Allocation concealment (yes/no/unknown) and blinding to pa-
tient, physician, and assessor (yes/no) were added in the as-
sessment form to counter the caveats of the Jadad scale.
Data synthesis and analysis
Baseline score, post-intervention score, and change from
baseline were entered into the database with their standard
deviations. Calculations were undertaken if needed to obtain
all these values based on the information provided.
PCE was calculated based on the following formula:
PCE ¼ Improvement in placebo group
Improvement in treatment group
where the numerator presents the contextual effect and the
denominator presents the contextual plus specific effects, i.e.
total treatment effect. PCE was log-transformed to normalise
the distribution. Standard error (SE) of the log(PCE) was cal-
culated using the Hedges method [12]. The standardised mean
change from baseline for the treatment group was calculated
to present the total treatment effect. In order to calculate the
PCE, only improvement of the outcome (e.g. pain relief) was
considered. No improvement from baseline (change score = 0)
or worsening (negative score) from baseline will be excluded
from this calculation. This is because the zero change score or
negative score does not permit log transformation of the PCE
and it is not a beneficial outcome relevant to the aims of
calculating the PCE. It also cannot explain why a treatment
worsens the targeted beneficial outcomes unless it is by
chance or an error. Therefore, we excluded them from the
PCE calculation. A random effects model was used to pool
the results with STATA, and the outcomes were stratified ac-
cording to treatment and other subgroup indicators. I2 index
was used to assess heterogeneity [13]. Publication bias was
examined using the funnel plot and Egger’s test [14]. Meta-
regression analysis (random effects regression) was undertak-
en if any subgroups showed substantial heterogeneity. The
PCE was presented together with the total treatment effect in
proportions to demonstrate both contributions from the spe-
cific treatment and non-specific contextual effects.
Data availability statement The dataset(s) supporting the con-
clusions of this article are available on request from the cor-
responding author.
Results
Selection of studies
In total, 3912 citations were retrieved from the systematic
literature search. Two hundred six duplicates were removed.
Two hundred eighty-six potentially eligible studies were iden-
tified from reading the abstracts. Full texts were obtained for
all 286 papers and 51 gave data for the PCE. A full list of the
included studies can be found in Appendix 1.
Characteristics of included studies
Of the 51 studies included in the primary analysis, 46 inves-
tigated pain, 30 investigated FIQ total, and 27 investigated
fatigue (Table 1).
Fig. 1 Study selection
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Proportion of contextual effect
The PCE for all treatments of fibromyalgia was 0.60 (95% CI
0·56 to 0·64) for pain, 0·57 (95% CI 0·53 to 0·61) for FIQ
total, and 0·63 (95% CI 0·59 to 0·68) for fatigue score
(Table 2). The heterogeneity between treatments varied ac-
cording to the outcome measured: I2=99.4% for pain,
I2=99.2% for FIQ total and I2=97.6% for fatigue.
Publication bias was detected in studies for pain and FIQ total
(p = 0.014 and p = 0.017, respectively). Figure 2 shows a for-
est plot for pain outcome.
Figure 3 presents the total treatment effect for pain outcome
and the proportion that is attributable to the contextual effect
for all treatment modalities. The length of the bar represents
the standardised total treatment effect for each treatment cate-
gory. The percentage is the proportion of contextual effect
(blue). Therefore, the remaining part of the bar is the specific
treatment effect (red).
Subgroup and meta-regression analyses
Subgroup analyses were carried out in order to examine the
predictors of PCE and to explore reasons for heterogeneity.
Some variations were observed for pain outcome, e.g. the
PCE increased with longer duration of treatment, higher pro-
portion of women, and greater number of participants
(Supplementary file 2). However, meta-regression analysis
confirmed that none of these factors was a predictor for pain
and only duration of treatment > 4 weeks was a predictor for
FIQ total (Table 3, Supplementary file 3).
Additional subgroup analysis was undertaken for FDA-
approved treatments for fibromyalgia, specifically duloxetine,
pregabalin, and milnacipran (www.fda.gov). For pain
outcomes, the PCE was 0.66 (95% CI 0.60 and 0.73) for
duloxetine, 0.58 (95% CI 0.56 to 0.60) for pregabalin, and 0.81
(95% CI 0.70 to 0.94) for milnacipran. For FIQ score, the PCE
was 0.66 (95% CI 0.59 to 0.74) for duloxetine, 0.70 (95% CI 0.
68 to 0.73) for pregabalin, and 0.65 (95% CI 0.58 to 0.72) for
milnacipran. Forest plots are presented in Supplementary file 4.
Discussion
This is the first study to emphasise the total treatment effect
and the proportion of this effect that may be attributable to
placebo/contextual effects using the RCT data in fibromyal-
gia. The study found that the majority of the total treatment
effect was contextual (60% for pain, 57% for FIQ, and 63%
for fatigue, respectively). This suggests that people with fibro-
myalgia benefit more from the contextual effects of a treat-
ment than from the specific treatment effect. More interesting-
ly, the proportion varied considerably between treatments,
ranging from 44% for electromagnetic therapy and analgesics
to 81% for milnacipran (Fig. 3). It is important to recognise
that many factors in routine clinical practice influence the
magnitude of placebo/contextual response such as patient’s
expectations and knowledge of being treated (‘placebo anal-
gesia’ [15]), patient education and patient-doctor interactions
(attentive and optimistic ‘positive consultation’, holistic as-
sessment, and desire to follow-up) [16].
This study presents a novel efficacy hierarchy for different
treatments based on the total treatment effect and presents the
proportion of the total treatment that is attributable to the spe-
cific and contextual effects (Fig. 3). This hierarchy has several
clinical implications: [1] it informs practitioners about the best
and the least effective treatments in fibromyalgia according to
overall treatment benefits, which is more likely to accord with
their experience in clinical practice than a hierarchy based on
Table 1 Summary of
characteristics of included studies Treatment Placebo
No. of participants 4795 4804
Mean age (range), year 48.8 (39.4–59.2) 48.58 (35.3–58.7)
Mean percentage of women (range), % 91.7 (39.2–100) 91.7 (61.8–100)
Median years of symptom (range) 7.8 (2.9–16.1) 7.9 (3.3–14.4)
Mean duration of treatment (weeks) 12.2
Jadad score, mean 4.47
Industry funding, n (%) 26 (51.0)
Dropout rate, n (%) 37 (72.5)
Random sequence, n (%) 32 (62.7)
Allocation concealment, n (%) 31 (61.0)
Blinding participants, n (%) 47 (92.2)
Blinding care provider, n (%) 34 (66.7)
Blinding assessors, n (%) 38 (74.5)
Intention to treat analysis, n (%) 26 (51.0)
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specific treatment effects [2]; it helps practitioners to appreci-
ate how important contextual effects are in clinical care for
people with fibromyalgia and suggests a way to improve cur-
rent healthcare delivery through optimisation of modifiable
contextual factors while waiting for new ‘stronger’ treatments
with high specific effect to be developed [3]; the hierarchy
highlights the areas that need further research, such as exercise
and other physical treatments, where contextual effect cannot
be calculated from RCTs because of the lack of a placebo
group due to difficulties in blinding. In addition, this study
has found that the PCE increases with the duration of treat-
ment (for pain) and sample size (for FIQ). These data may
prove useful firstly for trialists with respect to future design
of trials in fibromyalgia, and secondly for clinicians when they
manage the disease in clinical practice.
Comparison with other studies
The findings are similar to a meta-analysis of RCTs for
osteoarthritis where 75% of treatment effects are explained
by contextual effects [6]. The current meta-analysis concurs
that the majority of benefits observed in patients are attrib-
uted to contextual effects rather than the specific treatment
effects. This is not unexpected as both fibromyalgia and
osteoarthritis are characterised by chronic pain, restricted
function and fatigue, and often show some commonalities
in terms of central pain sensitisation [17]. The overall dif-
ference in PCE for pain outcomes (60 vs. 75%) between
these two conditions may reflect the nature of the disease
in that fibromyalgia is often more challenging and difficult
to treat than osteoarthritis.
Table 2 Summary of findings
Number of
studies included
Number of
participants
PCE 95%CI I2, % P
(Egger test)
Pain
Antidepressants 19 6399 0.668 0.616 to 0.725 99.5
CNS depressants 2 743 0.527 0.427 to 0.650 99.0
Anticonvulsants 2 516 0.504 0.387 to 0.655 98.5
Analgesics 2 356 0.440 0.371 to 0.520 83.2
Other medications 5 319 0.782 0.326 to 1.880 97.0
Electromagnetic therapy 9 390 0.442 0.221 to 0.885 98.9
Acupuncture 4 196 0.577 0.379 to 0.879 86.0
Others 3 178 0.548 0.339 to 0.888 86.7
Overall 46 9097 0.599 0.557 to 0.643 99.4 0.014
FIQ total
Antidepressants 11 4993 0.623 0.565 to 0.686 99.5
Anticonvulsants 3 890 0.527 0.456 to 0.608 97.8
CNS depressants 2 743 0.577 0.395 to 0.843 99.8
Analgesics 1 313 0.555 0.533 to 0.578 –
Other medications 4 292 0.687 0.502 to 0.940 90.5
Electromagnetic therapy 7 265 0.379 0.239 to 0.599 94.7
Acupuncture 1 49 0.634 0.482 to 0.835 –
Others 1 35 0.537 0.384 to 0.749 –
Overall 30 7580 0.569 0.530 to 0.612 99.2 0.017
Fatigue
Antidepressants 12 4733 0.625 0.578 to 0.674 97.5
Anticonvulsants 1 374 0.702 0.675 to 0.730
CNS depressants 2 743 0.547 0.473 to 0.633 98.3
Analgesics 1 313 0.808 0.773 to 0.845
Other medications 2 135 1.272 0.449 to 3.601 59.7
Electromagnetic therapy 6 263 0.396 0.221 to 0.708 90.3
Acupuncture 2 105 1.075 0.230 to 5.028 97.4
Others 1 62 0.330 0.165 to 0.661
Overall 27 6728 0.632 0.588 to 0.680 97.6 0.820
PCE proportion of contextual effect, CI confidence interval, I2 the variation in PCE attributable to heterogeneity, CNS central nervous system, FIQ
Fibromyalgia Impact Questionnaire
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Limitations of study
There are several caveats to this study. Firstly, like other meta-
analyses, heterogeneity may affect the outcomes. This is es-
pecially true for the primary outcome of pain where the studies
collected were highly heterogeneous (I2 = 99%). Although
subgroup analysis was carried out by treatment, high hetero-
geneity still existed in some treatments such as electromagnet-
ic therapy (Fig. 2). This may be due to the heterogeneity of
patients involved in the trials, although the majority of trials in
this meta-analysis used the ACR criteria for diagnosis. We
were unable to undertake a subgroup analysis based on differ-
ent diagnostic criteria or subsets so whether PCE varies accord-
ing to different diagnoses or subsets of fibromyalgia remains to
be investigated. Secondly, the number of trials available in
each treatment is different and ranges from 2 to 16; hence,
the total number of patients involved in each category varied
considerably (Fig. 2). Moreover, all studies for electromagnetic
therapy or acupuncture were less than 100 participants in size.
For small studies, it is not possible to get reasonable estimates
of the treatment effect and the proportion that may be attribut-
able to the context. Further, larger trials are needed to stabilise
Fig. 2 Forest plot of the proportion of contextual effect (PCE) for pain in fibromyalgia. PCE proportion of contextual effect, CI confidence interval, I2 the
variation in PCE attributable to heterogeneity, CNS central nervous system
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the estimates. Thirdly, apart from duration of treatment, we did
not find other predictors of PCE. This is not surprising as we
did not have individual patient data to explore the differences
in outcome between individual participants, only the differ-
ences between trials. Also, we have no information on factors
that influence expectancy, which has an important impact on
the magnitude of placebo and contextual response. For exam-
ple, we do not know the extent to which the treatment was
explained to participants and whether the information was giv-
en in a positive way. Furthermore, we have no information on
the illness perceptions and anxiety levels of each participant,
whether they have a catastrophizing or positive attitude, or
what expectations of treatment benefit they had. It can be as-
sumed that such factors will contribute to participant expectan-
cy and placebo/contextual response and that the overall expe-
rience and expectancy will differ between participants receiv-
ing the same treatment, even within the same trial. Fourthly,
only positive placebo effects were counted in PCE. Negative
placebo effects, e.g. nocebo effects, were excluded from the
analysis because of inability to log-transform negative results.
This may overestimate the contextual effect, but not PCE as the
latter is a ratio between placebo and treatment groups where
Fig. 3 Total treatment effect and
proportion of contextual effect in
fibromyalgia trials
Table 3 Meta-regression of
determinants of the proportion of
contextual effect (PCE) for pain
Variable Exp(β) SE 95% CI P value
Duration of treatment (≤ 4 weeks vs. > 4 weeks) 1.47 0.40 0.84 to 2.56 0.168
Proportion of female participants (%) 1.00 0.01 0.98 to 1.02 0.886
Number of participants (< 100 vs. ≥ 100) 1.09 0.20 0.74 to 1.59 0.665
Allocation concealment (yes vs. no) 0.94 0.20 0.62 to 1.43 0.767
Blinding (none vs. patient blinding vs. double blinding) 1.04 0.15 0.78 to 1.41 0.773
PCE proportion of contextual effect, CI confidence interval, Q heterogeneity statistic, I2 the variation in ES
attributable to heterogeneity, CNS central nervous system, FIQ Fibromyalgia Impact Questionnaire
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nocebo effects, if there are any, were excluded from both
groups under the assumption that treatment consists of active
ingredient and placebo. Furthermore, the results have not been
compared to studies with a no-treatment group. Therefore, it
has been assumed that all the improvements in the placebo
group are contextual. Some spontaneous improvement may
be due to regression to mean, natural disease fluctuation, or
artefact. However, because a proportion was calculated, these
spontaneous, non-treatment-related effects should be experi-
enced equally in the active and placebo arms. Under the as-
sumption of the multiplicative model, these spontaneous ef-
fects will be cancelled [10].
Conclusion and future research
This study found that a large amount of the treatment effect in
fibromyalgia RCTs is attributable to contextual response.
Further research needs to be done into what influences the
magnitude of this response. With this knowledge, physicians
could optimise the context in which they deliver treatment in
everyday practice and this would translate into the best possi-
ble outcomes for the patient. We suggest that a new hierarchy
according to the total treatment effect and the proportion at-
tributable to contextual effects better presents the strength of
treatment and will help dispel the efficacy paradox. However,
larger, higher quality trials are needed to establish this hierar-
chy with confidence.
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